DeFloria

Charlotte's Web announced that co-founder Jared Stanley stepped down from its board on June 3, 2026, to focus on his role as chief executive officer of DeFloria, Inc.

The autism community urgently needs better therapeutic options. Currently only two drugs are approved to address this condition, and both come with frequent adverse side effects.

Charlotte's Web Holdings says co-founder Jared Stanley leaves its board effective June 3, 2026, to focus on his CEO role at DeFloria, Inc. DeFloria is a clinical-stage botanical pharmaceutical company co-founded by Charlotte's Web, and the board has six directors following Stanley's resignation.

Jun 2026 · Newsfile CorpNews article

DeFloria’s botanical drug-development strategy for AJA001, an investigational full-spectrum hemp-derived oral drug for autism spectrum disorder, is validated by 2025 U.S. executive actions. The actions support cannabinoid drug development and expand research access.

Dec 2025 · PR NewswireNews article

AJNA BioSciences and Charlotte's Web schedule a panel at the Benzinga Cannabis Capital Conference featuring DeFloria leadership, including CEO Jared Stanley. The discussion focuses on cannabis's pharmaceutical future and the DeFloria botanical drug program.

Jun 2025 · PR NewswireNews article

DeFloria receives U.S. Food and Drug Administration clearance of its Investigational New Drug application for AJA001, an oral cannabinoid drug candidate. The clearance enables a Phase 2 clinical trial evaluating the drug for irritability associated with autism spectrum disorder (ASD).

Feb 2025 · PR NewswireNews article